<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748891</url>
  </required_header>
  <id_info>
    <org_study_id>D1330C00003</org_study_id>
    <secondary_id>EDRACT nbr 2007-006251-39</secondary_id>
    <nct_id>NCT00748891</nct_id>
  </id_info>
  <brief_title>DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)</brief_title>
  <official_title>Exploratory Open-Label, Non-randomised, Single Centre Methodology Study Comparing DCE-CT and DCE-MRI as Markers of Changes in Vascular Activity Mediated by a Positive Control Agent [Cediranib (Recentin™; AZD2171), a Potent Inhibitor of VEGF-driven Angiogenesis] in Patients With Advanced Solid Tumour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being carried out in patients with advanced solid tumours to assess which of
      two different types of imaging scans best measures activity of an experimental drug called
      Cediranib. The study compares the imaging tests: Dynamic Contrast Enhanced CT (DCE-CT) and
      Dynamic Contrast Enhanced MRI (DCE-MRI). It looks at which of these scans is the most
      accurate and best predicts a response to the treatment. Cediranib is thought to work by
      stopping blood flow to cancers, and both of these scans assess blood flow. Studying the
      response of cancers by measuring changes in their blood flow may provide useful information
      that will guide the way we manage cancers in the future.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in DCE-MRI and DCE-CT vascular parameters. Comparison between vascular parameters of each imaging modality and between modalities.</measure>
    <time_frame>DCE-MRI and DCE-CT scans taken at Baseline, Day 7 and Day 28. Comparison between modalities from scans taken on Days -8 and Day-1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline measurements for DCE-MRI-iAUC60(mMol/sec),Ktrans(min-1),ve,vp,kep(min-1,Enhancing Fraction% DCE-CT-Permeability Surface Product(ml/min/100g),Perfusion(ml/min/100g),Mean Transit Time(sec),Blood Volume (ml/100g),Positive Enhancement Integral(Hus).</measure>
    <time_frame>DCE-MRI and DCE-CT scans taken at Day -8, Day -1, Day 7 and Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response (RECIST )Progression free survival</measure>
    <time_frame>RECIST scans within 4 weeks prior to first dose then 8 weekly up to 24 weeks, then 12 weekly thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and on treatment time-point measurements for iAUC60 (mMol/sec) and Positive Enhancement Integral (Hus)</measure>
    <time_frame>DCE-MRI and DCE-CT scans taken at Day -8, Day -1, Day 7 and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recentin (Cediranib)</intervention_name>
    <description>30mg once daily, oral dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cediranib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic tumour which is refractory to standard therapies

          -  At least one lesion size ≥3cm on in longest diameter suitable for repeat assessment by
             DCE-CT and DCE-MRI

          -  Patients must be able to undergo DCE-CT and DCE-MRI scanning procedures

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Patients with hormone refractory prostate cancer (HRPC)

          -  Patients with a history of poorly controlled high blood pressure

          -  Ineligibility for MRI scanning or DCE-CT or DCE-MRI scanning
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Robertson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Alderley Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann De Bono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cancer Research, Royal Marsden Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Nick Botwood BSc, MBBS, MRCP, MFPM, Medical Science DirectoR, RECENTIN</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>tumour</keyword>
  <keyword>advanced sold tumour</keyword>
  <keyword>imaging</keyword>
  <keyword>DCE-CT Scan</keyword>
  <keyword>DCE-MRI scan</keyword>
  <keyword>Cediranib</keyword>
  <keyword>Recentin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

